Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-180-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
A toxicokinetic assessment has been performed, based on all physico-chemical properties and toxicological properties of the substance. This results in absorption rates derived for risk assessment of 50% for oral and dermal route of exposure and 100% for inhalation route of exposure.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Although CX-100 hydrolyses rather fast ( t1/2 is 4.3 hours at pH 7 and 25°C ), the present toxicokinetic assessment is based on CX-100 and not on its degradation product(s), as available physical/chemical properties are confined to CX-100. The moderate molecular size (467.6) and relatively high water solubility (34.9 g/L) of CX-100 are favourable for absorption via the gastrointestinal tract. Furthermore, the moderate log Pow value (between -0.6 – 1.4 at pH 4 to 10) is favourable for absorption by passive diffusion (1). However, the presence of ionisable groups will impair the absorption, as ionized substances do not easily pass the gastrointestinal
wall. Based on these physical chemical properties, for risk assessment purposes the oral absorption is set at 50%.
Once absorbed, distribution of the substance throughout the body is expected based on its moderate molecular weight and relatively high water solubility. Absorbed CX-100 might undergo conjugation (3). The conjugates will either be excreted via the bile (high molecular weight compounds) or the urine (low molecular weight compounds).
The low vapour pressure and high boiling point indicate that CX-100 is not readily inhaled as a vapour. The moderate log Po/w (between -0.6 – 1.4 at pH 4 to 10) is favourable for crossing the alveolar and capillary membranes. The relatively high water solubility of the substance indicates that CX-100 will dissolve in the mucus lining of the respiratory tract and will either be retained
there or subsequently be absorbed through aqueous pores. Based on its physical and chemical properties, it is likely that the substance will be absorbed after inhalation via the lungs. For risk assessment purposes the inhalation absorption of the substance is therefore set at 100%.
CX-100 being a liquid has the potential to partition from the stratum corneum into the epidermis. The moderate water solubility (34.9 g/L) and the partition coefficient (log Po/w -0.6 to 1.4 at pH 4 to 10) are also favourable for dermal absorption. Based on the molecular weight (467.6) and the log Po/w, the criterion for 100% dermal absorption as given in the Guidance (2) (MW < 500
and/or -1 < log Po/w < 4) is met. Based on these physical chemical properties, for risk assessment purposes the dermal absorption is set at 100%. It is, however, generally accepted that dermal absorption is lower compared to oral absorption. The 100% dermal absorption derived from the physical/chemical properties of the substance should therefore be considered as unrealistic worst case assumption. For risk assessment purposes a lower dermal absorption value of 50% is considered more appropriate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.